Immune complex-mediated glomerulonephritis is ameliorated by thrombin-activatable fibrinolysis inhibitor deficiency

Summary

The activity of plasmin plays a critical role in the development of chronic glomerulonephritis. Thrombin-activatable fibrinolysis inhibitor (TAFI) is a potent inhibitor of plasmin generation. We hypothesized thatTAFI is involved in the pathogenesis of glomerulonephritis because it inhibits plasmin generation. To demonstrate this hypothesis, we compared the development of immune complex-mediated glomerulonephritis in wild-type and TAFI-deficient mice. After six weeks of treatment with horse spleen apoferritin and lipoplysaccharide to induce glomerulonephritis, mice deficient in TAFI had significantly better renal function as shown by lower concentrations of albumin in urine and blood urea nitrogen compared to wild-type mice. In addition, the activity of plasmin and matrix metalloproteinases was significantly increased, and mesangial matrix expansion and the deposition of collagen and fibrin in kidney tissues were significantly decreased in TAFI-knockout mice as compared to their wildtype counterparts. Depletion of fibrinogen by batroxobin (Defibrase) treatment led to equalization of the renal function and the amount of collagen deposition in the kidneys of TAFI-knockout and wild-type mice with immune complex-mediated glomerulonephritis. Together these observations suggest that TAFI-mediated inhibition of plasmin generation plays a role in the pathogenesis of glomerulonephritis, and that it may constitute a novel molecular target for the therapy of this disease.

Keywords

Knockout mouse - glomerulonephritis - coagulation - fibrin - cyto-kines - plasmin - inflammation

• References

• 1 Hadban SJ, Atkins RC. Glomerulonephritis. Lancet 2005; 365: 1797-1806.
• 2 Nangaku M, Couser WG. Mechanisms of immune-deposit formation and the mediation of immune renal injury. Clin Exp Nephrol 2005; 03: 183-191.
• 3 Eddy AA. Molecular basis of renal fibrosis. Pediatr Nephrol 2000; 15: 290-301.
• 4 Hirschberg R. Wound healing in the kidney: complex interactions in renal interstitial fibrogenesis. J Am Soc Nephrol 2005; 16: 9-11.
• 5 Schnaper HW. Balance between matrix synthesis and degradation: a determinantof glomerulosclerosis. Pediatr Nephrol 1995; 09: 104-111.
• 6 Tomita M, Koike H, Han GD. et al. Decreased collagen-degrading activity could be a marker of prolonged mesangial matrix expansion. Clin Exp Nephrol 2004; 08: 17-26.
• 7 Uchio-Yamada K, Manabe N, Goto Y. et al. Decreased expression of matrix metalloproteinases and tissue inhibitors of metalloproteinase in the kidneys of hereditary nephritic (ICON) mice. J Vet Med Sci 2005; 67: 35-11.
• 8 Lijnen HR. Matrix metalloproteinases and cellular fibrinolytic activity. Biochemistry 2002; 67: 92-98.
• 9 Collen D. Ham-Wasserman lecture: role of the plasminogen system in fibrin homeostasis and tissue remodeling. Hematology Am Soc Hematol EducProgram 2001; 01: 1-9.
• 10 El-Nahas AM. Plasticity of kidney cells: role in kidney remodeling and scarring. Kidney Int 2003; 64: 1553-1563.
• 11 Liotta LA, Goldfarb RH, Brundage R. et al. Effect of plasminogen activator (urokinase), plasmin and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res 1981; 41: 4629-1636.
• 12 Laurens N, Koolwijk P, de Maat MP. Fibrin structure and wound healing. J Thromb Haemost 2006; 04: 932-939.
• 13 Hertig A, Rondeau E. Role of the coagulation/fibri-nolysis system in fibrin-associated glomerular injury. Am Soc Nephrol 2004; 15: 844-853.
• 14 Kitching AR, Holdsworth SR, Ploplis VA. et al. Plasminogen and plasminogen activators protect against renal injury in crescentic glomerulonephritis. J Exp Med 1997; 185: 963-968.
• 15 Matsuo S, Lopez-Guisa JM, Cai X. et al. Multifunctionality of PAI-1 in fibrogenesis: evidence from obstructive nephropathy in PAI-1-overexpressing mice. Kidney Int 2005; 67: 2221-2238.
• 16 Lee HB, Ha H. Plasminogen activator inhibitor-1 and diabetic nephropathy. Nephrology (Carlton) Suppl 2005; 10: S11-13.
• 17 Kamgar M, Nobakhthaghighi N, Shamshirsaz AA. et al. Impaired fibrinolytic activity in type II diabetes: correlation with urinary albumin excretion and progression of renal disease. Kidney Int 2006; 69: 1899-1903.
• 18 Fogo AB. Mechanisms in nephrosclerosis and hypertension-beyond hemodynamics. J Nephrol Suppl 2001; 04: S63-69.
• 19 Opatrny Jr K, Zemanova P, Opatrna S. et al. Fibrinolysis in chronic renal failure, dialysis and renal transplantation. Ann Transplant 2002; 07: 34-43.
• 20 Hertig A, Berrou J, Allory Y. et al. Type 1 plasminogen activator inhibitor deficiency aggravates the course of experimental glomerulonephritis through overactivation of transforming growth factor beta. FASEB J 2003; 17: 1904-1906.
• 21 Bajzar L. Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway. Arterioscler Thromb Vasc Biol 200 20: 2511-2518.
• 22 Schneider M, Nesheim M. A study of the protection of plasmin from antiplasmin inhibition within an intact fibrin clot during the course of clot lysis. J Biol Chem 2004; 279: 13333-13339.
• 23 Fujimoto H, Gabazza EC, Taguchi O. et al. Thrombin-activatable fibrinolysis inhibitor deficiency attenuates bleomycin-induced lung fibrosis. Am J Pathol 2006; 168: 1086-1096.
• 24 Nagashima M, Yin ZF, Zhao L. et al. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life. J Clin Invest 2002; 109: 101-110.
• 25 Welch TR, Blystone LW. C3 is central to the interstitial component of experimental immune complex glomerulonephritis. Clin Immunol 2005; 115: 80-84.
• 26 Bruno NE, Yano Y, Takei Y. et al. Protective role of thrombin activatable fibrinolysis inhibitor in obstructive nephropathy-associated tubulointerstitial fibrosis. J Thromb Haemost 2008; 06: 139-146.
• 27 Hideharu S, Reilly CM, Molano ID. et al. Complement component C3 is not required for full expression of immune complex glomerulonephritis in MRL/lpr mice. J Immunol 2001; 166: 6444-6451.
• 28 Kopp JB, Factor VM, Mozes M. et al. Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease. Lab Invest 1996; 74: 991-1003.
• 29 Ikeguchi H, Maruyama S, Morita Y. et al. Effects of human soluble thrombomodulin on experimental glomerulonephritis. Kidney Int 2002; 61: 490-501.
• 30 Mutch NJ, Moore NR, Wang E. et al. Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI. J Thromb Haemost 2003; 01: 2000-2007.
• 31 Sheerin NS, Springall T, Carroll M. et al. Altered distribution of intraglomerular immune complexes in C3-deficient mice. Immunology 1999; 97: 393-399.
• 32 Myles T, Nishimura T, Yun TH. et al. Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation. J Biol Chem 2003; 278: 51059-51067.
• 33 Yu XQ, Wu LL, Huang XR. et al. Osteopontin expression in progressive renal injury in remnant kidney: role of angiotensin II. Kidney Int 2000; 58: 1469-1480.
• 34 Sodek J, Batista Da Silva AP. et al. Osteopontin and mucosal protection. J Dent Res 2006; 08: 404-415.
• 35 Zhang G, Kernan KA, Collins SJ. et al. Plasmin(ogen) promotes renal interstitial fibrosis by promoting epithelial-to-mesenchimal transition: role of plasmin-activated signals. J Am Soc Nephrol 2007; 18: 846-859.
• 36 Swaisgood CM, French EL, Noga C. et al. The development of bleomycin-induced pulmonary fibrosis in mice deficient for components of the fibrinolytic system. Am J Pathol 2000; 157: 177-187.
• 37 Peters H, Noble NA, Border WA. Transforming growth factor-beta in human glomerular injury. Curr Opin Nephrol Hypertens 1997; 06: 389-393.
• 38 Baricos WH, Cortez SL, Deboisblanc M. et al. Transforming growth factor-beta is a potent inhibitor of extracellular matrix degradation by cultured human mesangial cells. J Am Soc Nephrol 1999; 10: 790-795.
• 39 Liu Y. Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol 2004; 15: 1-12.